Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9411MR)

This product GTTS-WQ9411MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ9411MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3338MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ10056MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ4478MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ15380MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ15722MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ8152MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ14542MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ1484MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW